Jazz Pharmaceuticals (JAZZ) Deferred Taxes (2012 - 2026)
Jazz Pharmaceuticals (JAZZ) posted quarterly Deferred Taxes of -$66.2 million for Q1 2026, down 51.14% year-over-year from -$135.5 million in Q1 2025, and down 4.57% quarter-over-quarter from -$63.3 million in Q4 2025.
Jazz Pharmaceuticals (JAZZ) Deferred Taxes (2012 - 2026) Analysis & Trends
Jazz Pharmaceuticals' Deferred Taxes history runs 15 years deep, the most recent figure standing at -$66.2 million for Q1 2026.
- In Q1 2026, Deferred Taxes fell 51.14% year-over-year to -$66.2 million; the TTM figure through Mar 2026 stood at -$467.4 million (down 151.62% YoY), while the FY2025 annual figure was -$445.0 million, down 113.59% from the prior year.
- Deferred Taxes for Q1 2026 stood at -$66.2 million, down from -$63.3 million in the prior quarter.
- The five-year high for Deferred Taxes was -$2.4 million in Q4 2024, with the low at -$271.4 million in Q3 2025.
- The 5-year median for Deferred Taxes is -$66.1 million (2023), against an average of -$74.8 million.
- The sharpest annual moves came in 2024 and 2025: Deferred Taxes soared 93.44% in 2024, then plunged 2588.28% in 2025.
- Jazz Pharmaceuticals' Deferred Taxes stood at -$145.4 million in 2022, then jumped by 75.31% to -$35.9 million in 2023, then jumped by 93.44% to -$2.4 million in 2024, then slumped by 2588.28% to -$63.3 million in 2025, then retreated by 4.57% to -$66.2 million in 2026.
- Business Quant data shows JAZZ's Deferred Taxes at -$66.2 million in Q1 2026, -$63.3 million in Q4 2025, and -$271.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Deferred Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -69.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 194.40 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -137,876.64 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 2.66 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Jazz Pharmaceuticals | 15.90 Bn | 14.28 Bn | 1.09 Bn | -38.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -38.70 Mn |
| Mar 31, 2026 | -66.20 Mn |
| Dec 31, 2025 | -63.31 Mn |
| Sep 30, 2025 | -271.41 Mn |
| Jun 30, 2025 | -66.45 Mn |
| Mar 31, 2025 | -43.80 Mn |
| Dec 31, 2024 | -2.36 Mn |
| Sep 30, 2024 | -64.40 Mn |
| Jun 30, 2024 | -75.18 Mn |
| Mar 31, 2024 | -66.39 Mn |
| Dec 31, 2023 | -35.90 Mn |
| Sep 30, 2023 | -78.92 Mn |
| Jun 30, 2023 | -79.33 Mn |
| Mar 31, 2023 | -66.06 Mn |
| Dec 31, 2022 | -145.38 Mn |
| Sep 30, 2022 | -64.56 Mn |
| Jun 30, 2022 | -36.98 Mn |
| Mar 31, 2022 | -45.34 Mn |
| Dec 31, 2021 | -27.40 Mn |
| Sep 30, 2021 | -74.99 Mn |